Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715591 | 1.00 | MAPT (0.59) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL714528 | 1.00 | MAPT (0.59) | MAPTGAAESR2SLC18A3SRD5A1 | |
| Ethylene SCHEMBL27953915 | 0.96 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| Hydrochloric Acid SCHEMBL9482313 | 0.96 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL2312546 | 0.94 | MAPT (0.57) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL18980773 | 0.94 | MAPT (0.57) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL31252385 | 0.92 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL29683554 | 0.92 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL3446977 | 0.92 | MAPT (0.55) | MAPTGAAESR2SLC18A3SRD5A1 | |
| SCHEMBL19524597 | 0.91 | MAPT (0.50) | MAPTGAAESR2SLC18A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2816040-B1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | CENTREXION THERAPEUTICS CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| CN-103724328-B | Cyclic pyrimidin-4-the methane amide of inflammation, asthma and COPD is used for the treatment of as CCR2 receptor antagonist | BOEHRINGER INGELHEIM INT (DE) | 2015-10-14 | — | — | CN | disclosed |
| EP-2379525-B1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INT (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| CN-101970394-B | Novel cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA AS | 2015-05-27 | — | — | CN | disclosed |
| EP-2513086-B1 | NOVEL ANTAGONISTS FOR CCR2 AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2816040-A1 | Process for the production of CCR2 receptor antagonists and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1595887-B1 | Chiral C2-symmetric biphenyls, preparation thereof as well as metal complexes containing these ligands and the use as catalysts in chirogene synthesis | CONSORTIUM ELEKTROCHEM IND (DE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1595887-A1 | Chiral C2-symmetric biphenyls, preparation thereof as well as metal complexes containing these ligands and the use as catalysts in chirogene synthesis | Consortium für elektrochemische Industrie GmbH (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20050250951-A1 | Chiral C2-symmetric biphenyls, their preparation and also metal complexes in which these ligands are present and their use as catalysts in chirogenic syntheses | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 2005-11-10 | — | — | US | disclosed |
| US-6878665-B2 | Diphosphines, their complexes with transisition metals and their use in asymmetric synthesis | SYNKEM (FR) | 2005-04-12 | — | — | US | disclosed |
| EP-1436304-B1 | NOVEL DISPHOSPINES, THEIR COMPLEXES WITH TRANSITION METALS AND THEIR USE IN ASYMMETRIC SYNTHESIS | SYNKEM (FR) | 2005-03-09 | — | — | EP | disclosed |
| US-20040260101-A1 | Novel diphosphines, their complexes with transisition metals and their use in asymmetric synthesis | SYNKEM (FR) | 2004-12-23 | — | — | US | disclosed |
| EP-1436304-A1 | NOVEL DISPHOSPINES, THEIR COMPLEXES WITH TRANSITION METALS AND THEIR USE IN ASYMMETRIC SYNTHESIS | Synkem (FR) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003029259-A1 | NOVEL DISPHOSPINES, THEIR COMPLEXES WITH TRANSITION METALS AND THEIR USE IN ASYMMETRIC SYNTHESIS | SYNKEM (FR) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | MAPT 4609/4885GAA 4503/4885ESR2 776/4885 |
| US-20040260101-A1 | Novel diphosphines, their complexes with transisition metals and their use in asymmetric synthesis | TPI1, TCP1, TTI2 | MAPT 4575/4885GAA 3078/4885ESR2 2970/4885 |
| US-20150065505-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | MAPT 4833/4885GAA 43/4885ESR2 1439/4885 |
| US-20050250951-A1 | Chiral C2-symmetric biphenyls, their preparation and also metal complexes in which these ligands are present and their use as catalysts in chirogenic syntheses | C1S, C2CD5, COASY | MAPT 3142/4885GAA 4237/4885ESR2 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.